Pfizer joins Roche, GSK in $32M round for Mission Therapeutics

Pfizer's ($PFE) venture arm has chipped in to a $32 million venture round for Mission Therapeutics, a Cambridge, U.K.-based biotech developing deubiquitylating enzyme inhibitors. Existing investors Sofinnova Partners, Imperial Innovations, S.R. One (GlaxoSmithKline) and Roche Venture Fund also contributed to the round. The drug developer is working on some preclinical programs for genetically defined cancers. The biotech is pursuing research initiated in the labs of Professor Stephen Jackson. "This investment represents one of the largest early stage financing rounds in the U.K. in the last 5 years and I am delighted that Pfizer has joined us," says Sofinnova's Graziano Seghezzi. "Besides the solid institutional investors, Sofinnova Partners and Imperial Innovations, Mission is now backed by the VC arms of three of the top 5 pharmaceutical companies in the world, testament to the quality of its science and drug discovery programs." Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.